Dupont De Nemours Inc
Change company Symbol lookup
Select an option...
DD Dupont De Nemours Inc
NRXPW NRX Pharmaceuticals Equity Warrant Exp 24 May 2026 *W EXP 05/24/2026
SAH Sonic Automotive Inc
PCRX Pacira Biosciences Inc
ONFO Onfolio Holdings Inc
LSPRU Larkspur Health Acquisition Corp
BKKT Bakkt Holdings Inc
PDI PIMCO Dynamic Income Fund
RNR Renaissancere Holdings Ltd
TSHA Taysha Gene Therapies Inc
Go

Materials : Chemicals | Mid Cap Blend
Company profile

DuPont de Nemours, Inc. provides technology-based materials and solutions. The Company's segments include Electronics & Industrial and Water & Protection. Its Electronics & Industrial segment is a global supplier of differentiated materials and systems for a range of consumer electronics, including mobile devices, television monitors, personal computers, and electronics used in a variety of industries. The segment is a provider of materials and solutions for the fabrication and packaging of semiconductors and integrated circuits. It also provides solutions for thermal management and electromagnetic shielding as well as metallization processes for metal finishing, decorative, and industrial applications. The Company's Water & Protection segment is a provider of engineered products and integrated systems for a range of industries, including, worker safety, water purification and separation, transportation, energy, medical packaging, and building materials.

Closing Price
$69.02
Day's Change
-2.23 (-3.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
70.74
Day's Low
69.06
Volume
(Average)
Volume:
2,707,790

10-day average volume:
2,705,317
2,707,790

Albireo to Participate in Upcoming Investor Conferences

8:00 am ET September 1, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:ALBO), EQNX::TICKER_END Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in upcoming investor conferences:

Simon Harford, Chief Financial Officer, and Colleen Alabiso, SVP, Corporate Affairs, will host meetings with investors.

-- Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022

Ron Cooper, President and Chief Executive Officer, will be participating in a fireside chat from 10:30 - 11:00 am ET. Ron Cooper and Simon Harford will host meetings with investors.

-- H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022

Pamela Stephenson, Chief Commercial Officer, will participate in a fireside chat available on September 12 at 7:00 am ET. Pamela Stephenson and Christine Clemson, SVP, Head of Global Medical Affairs, will conduct investor meetings on September 12.

-- Baird 2022 Global Healthcare Conference on Tuesday, September 13, 2022

Ron Cooper will be presenting from 8:30 - 9:00 am ET. Ron Cooper and Simon Harford will host meetings with investors.

A replay of all webcasts will be available on-demand on the Albireo Investors page ir.albireopharma.com.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo's lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe, Bylvay has been approved for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with global Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Media Contacts:

Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com

Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:

Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

https://ml.globenewswire.com/media/8eef1fda-a775-421e-9f49-804f467ece7e/small/albireo-logo-jpg.jpg

https://ml.globenewswire.com/media/8eef1fda-a775-421e-9f49-804f467ece7e/small/albireo-logo-jpg.jpg

comtex tracking

COMTEX_413514668/2010/2022-09-01T08:00:04

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.